Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2001

View Archived Issues

Enrollment closed in Atrix's phase III trial with four-month Leuprogel

Arena and Taisho establish receptor discovery alliance

Dey receives FDA approval for first dual-therapy nebulizer solution for use in COPD

InterMune and Boehringer Ingelheim establish codevelopment agreement for interferon gamma-1b

Intravenous formulation of Protonix approved by FDA for GERD

PAK-200 shows cardioprotective effects in guinea pig myocardium

Mechanism of gastroprokinetic effects of Z-338 discussed at recent scientific meeting

Progen and Griffith University to discover new compounds to treat inflammatory diseases

BioChem Pharma's Troxatyl enters late-stage clinical trials in AML patients

Abgenix and Diabetogen collaborate on development of anti-CD28 antibody therapy

AtheroGenics commences phase I trial with AGIX-4207 for treatment of RA

MoliChem's aerosol product for CF undergoes phase Ib clinical trials

Profile, status of Lorus's lead cancer therapeutics discussed at AACR meeting

Antitumor and antiangiogenic effects demonstrated for new VEGF-binding molecule

Peptidomimetic and small-molecule uPA inhibitors hold promise as cancer therapeutics

German launch of antimigraine Almogran imminent

Johnson & Johnson and Alza agree to merge

ROCK inhibitors investigated for potential as antiglaucoma drugs

Recently approved IOP-lowering prostaglandin highlighted at Prague glaucoma meeting

Ciclesonide to be codeveloped and copromoted by Aventis and Altana for asthma

Replagal receives positive opinion in E.U. for treatment of Fabry's disease

Camptosar approved in Canada as first-line treatment of metastatic colorectal cancer

Tryptase inhibitors and use in respiratory disorders claimed by Byk Gulden

Bayer presents newest angiogenesis inhibitor series

Substituted aromatic compounds from Takeda inhibit NO production

Novel alpha1A/1B-adrenoceptor antagonists and use in BPH and pain

Meiji Seika synthesizes dual integrin and fibrinogen antagonists

Neurotrophic agents discovered at Teijin presented in recent patent

Potential new ribonucleotide reductase inhibitors may be more effective than hydroxyurea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...